authors
- Knox, J J
- Barrios, C H
- Kim, T M
- Cosgriff, T
- Srimuninnimit, V
- Pittman, K
- Sabbatini, R
- Rha, S Y
- Flaig, T W
- Page, R D
- Beck, J T
- Cheung, F
- Yadav, S
- Patel, P
- Geoffrois, L
- Niolat, J
- Berkowitz, N
- Marker, M
- Chen, D
- Motzer, Robert John
Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.
Overview
publication date
- November 1, 2018
published in
Identity
PubMed Central ID
- PMC6290878
Scopus Document Identifier
- 85058593544
Digital Object Identifier (DOI)
- 10.1093/annonc/mdx807
PubMed ID
- 29390043
Additional Document Info
volume
- 29
issue
- 11